Home › Lung Diseases › NCT05147688

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for Pulmonary Diseases

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Pulmonary Diseases

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of pulmonary disease
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur

About the study

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Pulmonary Diseases

What is being tested

• cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 20 · Started: Dec 1, 2021

Contact the study team

• Chadwick Prodromos, MD · Phone: 847-699-6810

Official record on ClinicalTrials.gov — NCT05147688

Locations in the U.S.

Conditions

• Lung Diseases
• Asthma
• COPD

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.